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We produced nine monoclonal antibodies (MAbs) directed against the West Nile virus E glycoprotein using three different immunization
strategies: inactivated virus, naked DNA, and recombinant protein. Most of the MAbs bound to conformation dependent epitopes in domain
III of the E protein. Four of the MAbs neutralized WNV infection and bound to the same region of domain III with high affinity. The
neutralizing MAbs were obtained from mice immunized with inactivated virus alone or in combination with a DNA plasmid. In contrast,
MAbs obtained by immunization with a soluble version of the E glycoprotein did not exhibit neutralizing activity. These non-neutralizing
antibodies were cross-reactive with several other flaviviruses, including Saint Louis encephalitis, Japanese encephalitis, Yellow Fever and
Powassan viruses. Interestingly, some non-neutralizing MAbs bound with high affinity to domains I or III, indicating that both affinity and
the precise epitope recognized by an antibody are important determinants of WNV neutralization.
D 2005 Elsevier Inc. All rights reserved.
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West Nile virus (WNV), the etiologic agent of West
Nile virus fever and encephalitis, is an emerging human
and veterinary pathogen in the Western Hemisphere. WNV
was first isolated in the United States in 1999, and has
since spread rapidly throughout North America and the
Caribbean. WNV is a member of the genus Flavivirus,
family Flaviviridae, and is related to other arthropod-
borne viruses including dengue virus, Japanese encepha-
litis virus, Saint Louis encephalitis virus and tick-borne
encephalitis virus. Phylogenetic analysis demonstrates that
two related groups of WNV exist in nature (lineage I and
II), though only lineage I viruses have been associated
with disease outbreaks worldwide, including the current0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: doms@mail.med.upenn.edu (R.W. Doms).epidemic in the United States (Berthet et al., 1997;
Lanciotti et al., 1999).
WNV virions contain two surface glycoproteins, pre-
membrane/membrane (prM/M) and envelope (E). The
membrane protein (M) is synthesized as a precursor (prM)
that acts as a chaperone during the folding and maturation of
the E protein (Konishi and Mason, 1993; Lorenz et al.,
2002). Flavivirus prM and E proteins form a heterodimer
(Allison et al., 1995a; Wengler and Wengler, 1989) with
prM probably protecting the E protein from acid inactiva-
tion during transport in intracellular vesicles (Heinz and
Allison, 2000). After cleavage of prM into M by furin
during intracellular transport (Stadler et al., 1997), dissoci-
ation of the prM/E heterodimer occurs and E homodimers
are formed (Kuhn et al., 2002; Zhang et al., 2003). E dimers,
arranged in a bherringboneQ pattern, form a protein shell on
the surface of mature flavivirus virions (Kuhn et al., 2002;
Mukhopadhyay et al., 2003). The E protein is responsible005) 70–82
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neutralizing antibodies. Structural studies of tick-borne
encephalitis virus and dengue virus reveal that the E protein
of flaviviruses folds into three structural domains: I, II and
III (Modis et al., 2003; Rey et al., 1995). Domain I, the
central domain, contains a single N-linked glycosylation site
and forms part of a hinge region that undergoes conforma-
tional changes upon exposure of the protein to low pH, in
conjunction with Domain II (Bressanelli et al., 2004; Modis
et al., 2004). Domain II, the dimerization domain, contains a
highly conserved hydrophobic loop which inserts into the
host cell membrane during fusion (Allison et al., 2001;
Bressanelli et al., 2004; Modis et al., 2004). Domain III is
the putative receptor binding domain (Bhardwaj et al., 2001;
Crill and Roehrig, 2001; Hung et al., 2004) and an
important target for neutralizing antibodies. Antibodies that
bind to the E protein could prevent infection of cells by
blocking attachment of virus to cellular receptors and
attachment factors (Crill and Roehrig, 2001; He et al.,
1995), or by blocking fusion with the cell membrane after
viral attachment (Butrapet et al., 1998; Gollins and Porter-
field, 1986; Guirakhoo et al., 1991; Roehrig et al., 1998;
Stiasny et al., 2002).
Several lines of evidence suggest an important role for
antibodies in protection from and clearance of WNV. Passive
immunization with antibodies against WNV can prevent
disease in animals infected with WNV (Ben-Nathan et al.,
2003; Camenga et al., 1974; Diamond et al., 2003; Engle and
Diamond, 2003; Tesh et al., 2002; Wang et al., 2001). In
addition, B-cell-deficient mice are more susceptible to WNV
than mice with an intact humoral immune system (Diamond
et al., 2003; Halevy et al., 1994). Clinical case reports of
human WNV patients who exhibited neurologic symptoms
but recovered after treatment with human immunoglobulin
preparations containing WNVantibodies suggest that admin-
istration of WNV-specific antibodies could be of therapeuticTable 1
Characterization of monoclonal antibodies (MAbs) against West Nile virus
MAb Immunization Isotype Viral protein
17C8 Formalin inactivated virus IgG1 Envf
8B10 Formalin inactivated virus IgG1 Env
10C5 Formalin inactivated virus IgG1 Env
17D7 DNA + Formalin inactivated virus IgG2a Env
11C2 DNA + Formalin inactivated virus IgG1 Env
6G10 DNA + Formalin inactivated virus IgG1 Env
4E1 Soluble Env IgG2b Env
3F7 Soluble Env IgG1 Env
9E5 Soluble Env IgG1 Env
a WB—Western blot. Samples were analyzed either by addition of reducing agent
(NR).
b IF—immunofluorescence.
c IP—immunoprecipitation.
d Average PRNT50 values were obtained with at least 4 replicates of the PRNT a
e Kd measurements represent averages of three experiments done in duplicate.
f Env—WNV envelope protein.
g +/ less efficient in assay.
h N/A—data not available for non-neutralizing antibodies.value (Agrawal and Petersen, 2003; Haley et al., 2003;
Hamdan et al., 2002; Shimoni et al., 2001).
Relatively few monoclonal antibodies (MAbs) against
WNV have been described and fully characterized (Adams et
al., 1995; Beasley and Barrett, 2002; Besselaar and Black-
burn, 1988; Hall et al., 1991; Mathiot et al., 1990; Peiris et
al., 1982). Using three different immunization strategies, we
produced and characterized nine MAbs against WNV. Most
of the MAbs bound to conformation-dependent epitopes in
domain III and reacted with a lineage I and lineage II virus
strain. MAbs produced by immunization with a soluble form
of the E protein cross-reacted with several other flaviviruses,
but did not exhibit virus-neutralizing activity. MAbs
produced by immunization with a formalin-inactivated virus
vaccine, or a combination of formalin-inactivated vaccine
and a DNA vaccine, were WNV-specific and a subset
neutralized virus infection. For antibodies that blocked
WNV infection, neutralization potency correlated with
binding affinity. However, some non-neutralizing MAbs
bound with high affinity to epitopes that partially overlapped
with those recognized by neutralizing MAbs. Thus, rela-
tively subtle differences in MAb binding to the E protein can
significantly impact virus neutralization.Results
Production of MAbs to the Envelope proteins of WNV
Immunization with different forms of flavivirus envelope
proteins has the potential to produce antibodies with
different properties (Aberle et al., 1999; Heinz et al.,
1995; Raviprakash et al., 2000). To increase the possibility
of obtaining MAbs to a variety of epitopes, we employed
three different methods to produce and deliver WNV
immunogens (see Table 1). In the first immunizationWBa IFb IPc PRNT50 Average (Ag/ml)d Kd (nM)e
NR + + N250 2.61
NR + + 1.7 0.09
NR + + 19.4 2.01
R/NR + +/g N/Ah 0.83
NR + + 4.1 0.24
NR +  N/A 29.5
R/NR + + N/A 0.06
R/NR +  N/A 32.41
NR + +/ N/A 1.27
and heat treatment (R), or without reducing agent and without heat treatment
ssay.
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virus vaccine licensed for horses (West Nile Innovator-Fort
Dodge Animal Health) (Ng et al., 2003). In the second
protocol, mice were vaccinated with a DNA plasmid
encoding lineage I WNV surface glycoproteins prM and E
(pCBWN) (Davis et al., 2001), followed by booster
injections with the formalin-inactivated virus vaccine. The
third immunization protocol utilized a soluble form of the
WNV E protein produced by expressing a truncated form of
E protein lacking the two transmembrane anchors as a
polyprotein with prM, a configuration shown previously to
allow interaction of E with prM and secretion from cells
(Allison et al., 1995a).
Hybridomas were screened by ELISA using two different
antigens, subviral particles (SVPs) or soluble E protein,
depending on the immunogen utilized. For mice immunized
with DNA and the formalin-inactivated virus vaccine,
subviral particles (SVPs) were used as the antigen. SVPs
are secreted from cells expressing full-length prM and E
proteins, and closely resemble native virus particles
antigenically and functionally (Allison et al., 1995a; Chang
et al., 2000; Davis et al., 2001; Hunt et al., 2001; Konishi
and Fujii, 2002; Konishi et al., 1992, 2001; Kroeger and
McMinn, 2002; Mason et al., 1991; Schalich et al., 1996).
Since SVPs are not infectious, they can substitute for virus
in a variety of assays and were chosen as the antigen for
these ELISAs. For mice immunized with the soluble E
protein, the same soluble protein was used as the antigen in
the screening ELISA. Three MAbs were obtained from each
immunization approach: formalin-inactivated virus (17C8,
8B10, 10C5), DNA followed by formalin-inactivated virus
(17D7, 11C2, 6G10) and soluble E (4E1, 3F7, 9E5)
(Table 1). These MAbs were isotyped, purified from hybri-
doma supernatants and immunoglobulin concentrations de-
termined by ELISA.
Characterization of MAbs
To determine which viral surface glycoprotein the MAbs
recognized and to discriminate between MAbs recognizing
linear and discontinuous epitopes, we examined the ability of
the MAbs to detect prM or E by immunoblotting. 293T cells
were transfected with pCBWN, and cell lysates analyzed
under two different conditions in SDS-PAGE: complete and
partial denaturation. All MAbs recognized the E protein by
immunoblot under partially denaturing conditions (NR),
while three of the MAbs (17D7, 4E1, 3F7) also recognized
the E protein under fully denaturing conditions (R) (Table 1,
data not shown). This suggests that six of the MAbs are
directed against discontinuous epitopes in the E protein,
while three of the MAbs (17D7, 4E1 and 3F7) recognized
epitopes that persist after denaturation and reduction.
We next determined if the MAbs could detect WNV E
protein expressed in cells transfected with pCBWN by
immunofluorescence and immunoprecipitation techniques
(Table 1). Using immunofluorescence, all MAbs detected anintracellular reticular pattern consistent with localization of
the E protein in the endoplasmic reticulum, as previously
described (Mackenzie and Westaway, 2001, Hanna et al.,
manuscript in preparation) (data not shown). Seven out of
nine MAbs immunoprecipitated the E protein from cell
lysates, although two of these MAbs (17D7 and 9E5) were
less efficient than the others (data not shown). These seven
MAbs also co-immunoprecipitated the prM protein from
cell lysates, confirming that prM and E form stable
complexes within the cell (Lorenz et al., 2002). Two MAbs
did not immunoprecipitate E under these conditions, 3F7
and 6G10, suggesting that these MAbs may recognize
epitopes that are either lost upon detergent extraction, buried
when E exists in a complex with prM or another E
monomer, or may have a lower affinity towards the
detergent solubilized E protein.
Epitope mapping
Based on the crystal structures of the E protein from
dengue virus and tick-borne encephalitis virus, the E protein
of WNV folds into three structural domains (Fig. 1A) (Modis
et al., 2003; Rey et al., 1995). Three different techniques were
used to further define the epitopes recognized by the panel of
MAbs on the WNV E protein: production of E protein
fragments as bacterial fusion proteins, competition binding
ELISA studies, and site-directed mutagenesis of the E
protein. Small fragments of the E protein ectodomain were
produced in bacteria as thioredoxin fusion proteins, termed
WE1 through 7 (Fig. 1B). Lysates of bacteria expressing the
different fragments were run on SDS-PAGE under partially
denaturing conditions, and antibody recognition of the
fragments assessed by immunoblotting. Six of the nine
MAbs recognized fragment WED3, which consisted of
residues 296–415 of domain III from lineage I WNV strain
NY99-6480 (Fig. 1C). For West Nile and other flaviviruses,
production of domain III by itself in bacteria results in a
molecule whose conformation is similar to that of domain III
in the native E protein (Bhardwaj et al., 2001; Volk et al.,
2004;Wu et al., 2003; Yu et al., 2004). However, these MAbs
failed to map to smaller fragments of domain III (WED3-1,
WED3-2, WED3-3), suggesting that they recognized con-
formational epitopes conserved in the bacterial protein
encoding the majority of domain III, but lost when domain
III was disrupted. One MAb, 17D7, mapped to two frag-
ments, WE2 (residues 146–249) and WE4 (residues 130–
193), indicating that its epitope mapped to domain I. Two
MAbs, 6G10 and 9E5, did not recognize any of the E protein
fragments by immunoblotting. When reactivity was assessed
by ELISAwith a subset of non-denatured protein fragments,
9E5 reacted with WED3 (Domain III), suggesting that its
epitope was conformationally sensitive, while 6G10
remained nonreactive.
To determine if the MAbs bound to overlapping epitopes
on the surface of the E protein, we tested the MAbs using a
competition binding ELISA. For these studies, SVPs were
Fig. 1. Epitope mapping by immunoblot and ELISA against E protein
fragments. (A) Ribbon diagram model of the WNV E protein based on the
crystal structure of the Dengue E protein (PDB 1OAN) obtained using the
program 3D-Jigsaw and visualized with Rasmol 2.6. Domains are color
coded: domain I in red, domain II in yellow, and domain III in blue. Inset
shows an enlarged version of Domain III with mutated amino acid residues
important for antibody binding depicted in different colors (residues 306,
307, 330, 332) (results shown in Table 3). These residues are located on the
lateral surface of Domain III. Mutated residues which did not affect
antibody binding are colored in orange. (B) Linear diagram of WNV E
protein with domains color coded as in A. Boxes below diagram depict
approximate delimitations of WNV E protein fragments produced as
bacterial fusion proteins. (C) Results from immunoblot and ELISA analyses
of MAb recognition of the WNV E protein fragments. The fragment(s)
recognized by each MAb is listed, as well as domain assignments.
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concentrations of unlabeled MAbs were incubated with the
SVPs, after which a biotinylated bcompetitorQ MAb was
added. If preincubation of SVPs with an unlabeled MAb
blocked subsequent binding of a biotinylated MAb, it can be
concluded that the MAbs bind to similar or at least
overlapping epitopes. The MAbs were categorized into six
groups based on the results of this competition-binding
assay (Fig. 2D). MAbs 17D7 and 6G10 did not compete
significantly with any of the other MAbs tested, although
17D7, which mapped to domain I, partially blocked bindingof several domain III MAbs (Figs. 2A and B). MAbs which
mapped to domain III were categorized into four different
groups. The first group consisted of MAbs 8B10, 11C2,
10C5 and 17C8. When 8B10 or 11C2 were used as the
unlabeled antibody, biotinylated 17C8 or 10C5 were not
able to subsequently bind to the antigen (Fig. 2A and data
not shown). However, when MAbs 10C5 or 17C8 were used
as the unlabeled antibody, 8B10 and 11C2 were able to
subsequently bind antigen (Fig. 2B and data not shown).
This non-reciprocal competition is most likely due to the
fact that 17C8 and 10C5 bound to E protein with a lower
affinity than MAbs 8B10 and 11C2 (see Table 1). Thus, we
conclude that these four MAbs bind to essentially the same
epitope on domain III. The other three domain III MAbs,
4E1, 9E5 and 3F7, did not significantly compete with any of
the other MAbs tested in this assay, although some partially
blocked binding of other domain III MAbs (data not
shown). Partial competition could be due to differences in
affinity, to antibody-induced conformational changes in E
protein upon antibody binding or steric hindrance. For
example, binding of a domain I MAb to one E monomer
could partially prevent binding of a domain III MAb to an
adjacent E monomer, as was seen with MAb 17D7.
Site-directed mutagenesis of the E protein was used to
investigate the specific amino acid residues important for
binding of domain III antibodies. Mutations of specific
amino acid residues were made based on analysis of the
structure of the WNV and Dengue E proteins (Modis et al.,
2003; Volk et al., 2004), and MAb mapping results with
neutralization escape mutants from other flaviviruses and
WNV (Beasley and Barrett, 2002; Roehrig, 2003). All
studied amino acid residues were mutated to alanines,
except for two mutations (positions 307 and 330) previously
described as important targets for WNV neutralizing anti-
bodies (Beasley and Barrett, 2002). SVPs were produced by
transfection of 293T cells, and attached to the ELISA wells.
Binding of each MAb to the mutant SVPs was normalized
to binding of the MAb to the wild-type SVP, and shown as
percentage of wild-type binding (Table 3). Results from site-
directed mutagenesis confirmed that MAbs 8B10, 10C5,
17C8 and 11C2, which bind to domain III and compete in
the competition binding assay, map to the same cluster of
amino acid residues on the lateral surface of domain III
(including residues 306, 307, 330 and 332) (Table 3),
though the contacts made with this small region of domain
III varied slightly between the antibodies. All four MAbs
were affected by mutations in residues 307 and 330, while
only MAb 17C8 was affected by the mutation in 306, and
MAb 11C2 affected by the mutation in 332 (Table 3). This
area of Domain III has been described previously as a target
of potent neutralizing MAbs for a variety of flaviviruses,
including WNV (Beasley and Barrett, 2002; Chambers et
al., 1998). Additional mutagenesis of neighboring residues
on the lateral surface of domain III did not significantly
affect binding of specific MAbs (Table 3). Interestingly,
mutations that prevented binding of neutralizing MAbs did
Fig. 2. Epitope mapping by competition binding ELISA. Representative results from competition ELISAs are shown in panels A, B and C. WNV lineage I
SVPs were captured to ELISA wells and then incubated with saturating amounts of the indicated unlabeled MAb. Sub-saturating amounts of the biotinylated
MAbs (17C8 in A, 11C2 in B, and 17D7 in C) were then added. After washing, streptavidin-HRP was added to measure the amount of bound, biotinylated
MAb. The amount of binding obtained in the absence of unlabeled antibody was set to 100% for each biotinylated MAb. Data represents the average of two
independent experiments done in duplicate, with the error bars representing the standard error. (D) Group assignments of MAbs based on competition binding
assay. MAbs binding to overlapping epitopes are grouped in the same circle, while non-competing MAbs are grouped individually.
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these residues are not critical for function of the E protein,
as previously suggested (Beasley and Barrett, 2002).
Since the E protein of flaviviruses undergoes irrever-
sible conformational changes at low pH (Allison et al.,
1995b; Bressanelli et al., 2004; Heinz and Allison, 2000;
Modis et al., 2004), we studied if any of the epitopes
recognized by these MAbs were affected by treatment of
virus with low pH. While domain III epitopes are usually
not affected by low pH treatment, domain I and II
epitopes can be altered or lost due to the large
rearrangements that occur in these domains at low pH
(Bressanelli et al., 2004; Modis et al., 2004; Roehrig,
2003). West Nile virions were treated at low pH (pH 4)
or neutral pH (pH 8), back-neutralized to pH 8 and used
as the antigen in an ELISA. Plaque assays showed that
low pH treated virus was inactivated while virus treated
at neutral pH remained infectious, confirming that low
pH treatment triggered irreversible conformational
changes in the E protein that inhibited virus entry and
infection (data not shown). However, all MAbs recog-
nized viruses treated at low or neutral pH, indicating that
the epitopes recognized by these MAbs were not lost
during the pH-induced conformational changes although
small differences in the reactivity of the antibodies were
sometimes observed (data not shown).Cross-reactivity of MAbs with Lineage II WNV and other
flaviviruses
We examined if the MAbs would recognize a prototypic
lineage II E protein (WNV 956 D117 3B) (Yamshchikov et
al., 2001) in addition to the lineage I E protein described
above. The E proteins of these two strains differ in 25 out of
502 amino acid residues, with the Lin II strain lacking a
glycosylation site (Yamshchikov et al., 2001). For these
experiments, we used a lineage II envelope protein which
had the glycosylation site inserted by mutagenesis, as we
have found that this results in higher levels of SVP
production (Hanna et al., manuscript in preparation).
Lineage I and II SVPs were obtained by transfecting cells
with plasmids encoding the prM and E proteins from each
strain. The SVPs were captured to the wells of an ELISA
plate and incubated with each of the MAbs. All MAbs
detected both lineage I and II SVPs, although some MAbs
had decreased reactivity to lineage II relative to lineage I
(17D7, 6G10, 3F7), suggesting subtle antigenic differences
may exist between these two strains (data not shown).
Given the close phylogenetic and antigenic relationships
between flaviviruses, we tested each MAb for the ability to
cross-react with a panel of related flaviviruses. Vero cells
were infected with the indicated virus (Table 2), after which
immunofluorescence was performed. We found that three of
Table 2
Analysis of cross-reactivity of MAbs against other flaviviruses by
immunofluorescence
WNV = West Nile Virus, SLE = Saint Louis Encephalitis Virus, JEV =
Japanese Encephalitis Virus, YFV = Yellow Fever Virus, POW = Powassan
Virus. The numbers on the table refer to fluorescence intensity with 4 = to
highest intensity and 0 = no staining. Only MAbs which showed cross-
reactivity are shown (shaded boxes).
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flaviviruses. These threeMAbs recognized not only members
of the Japanese encephalitis serocomplex (Saint Louis
encephalitis and Japanese encephalitis virus), but also more
distantly related flaviviruses (Yellow Fever and Powassan
virus) (Table 2). None of theMAbs reactedwith Dengue virus
2, nor with the other viruses tested (Western Equine
Encephalitis virus, Venezuelan Equine Encephalitis virus,
Eastern Equine Encephalitis virus, LaCrosse virus). Only the
threeMAbsmade by immunization with the soluble E protein
showed cross-reactivity in this assay, while the remaining six
MAbs made by immunization with DNA or formalin-
inactivated virus were specific for WNVepitopes.
Neutralization profiles of MAbs
The neutralization profile of the MAbs was assessed
using a plaque reduction neutralization assay. Four MAbs
(11C2, 17C8, 10C5 and 8B10), all of which bound to the
same or highly similar epitopes in domain III, showed
neutralizing activity using this approach, albeit with differ-
ent potency (Table 1). MAbs 8B10, 11C2 and 10C5 showedTable 3
Epitope mapping by site-directed mutagenesis
Results of MAb binding to wild-type (WT) or mutated E proteins in the context of
100%, and binding of each MAb to the mutated E proteins was expressed as a p
significantly affected binding of specific MAbs. Location of these mutations is
independent experiments done in duplicate.the strongest neutralizing activity, while MAb 17C8 only
neutralized WNV when very high concentrations of anti-
body were present (N250 Ag/ml). Among the four neutraliz-
ing MAbs, those that bound with the highest affinity
exhibited the most potent neutralization activity (Table 1).
However, high affinity binding alone did not predict
neutralizing activity since some MAbs that failed to
neutralize WNV also bound with high affinity (i.e., 4E1,
17D7) (Table 1). Therefore, both affinity and the specific
epitope recognized by the antibody are important determi-
nants for neutralization of WNV.Discussion
West Nile virus, an emerging infectious pathogen in the
Western Hemisphere, is responsible for viral encephalitis
epidemics worldwide. The importance of an intact anti-
body response for reducing morbidity and mortality of
WNV infected animals has been established through
studies in animal models (Diamond et al., 2003; Halevy
et al., 1994), though the nature and character of the
humoral immune response in humans and other important
animal hosts for WNV is not well understood. In humans,
several case reports suggest that neutralizing antibodies
may have a role in recovery from WNV infection
(Agrawal and Petersen, 2003; Haley et al., 2003; Hamdan
et al., 2002; Shimoni et al., 2001). In order to develop
systems to understand the neutralization of WNV by
antibodies both in vivo and in vitro, we produced a panel
of MAbs to the E glycoprotein of WNV and mapped their
epitopes by several techniques.
To increase the probability of obtaining a diverse
repertoire of MAbs, we utilized four different strategies to
elicit WNV specific MAbs. First, we utilized a formalin-subviral particles (SVP). The binding of each MAb to WT SVPs was set to
ecentage of WT binding. Shaded in gray are results from mutations which
depicted in Fig. 1A. Data in each table represent mean values from two
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efficacy in horses, although the humoral response that it
elicits has not been extensively characterized (Ng et al.,
2003). While formalin-inactivation may alter the antigenic
conformation of the surface glycoproteins, increasing the
possibility of obtaining antibodies against epitopes that may
differ from those in the native virus (Heinz et al., 1995),
formalin-inactivated human vaccines have been successfully
used for other flaviviruses (Barrett, 2001; Nalca et al.,
2003). Second, we immunized mice with a nucleic acid
construct encoding the prM and E proteins of WNV
(pCBWN). Immunization with this DNA was expected to
result in the production of subviral particles that closely
reflect native WNV structure. Previous studies demonstrate
that vaccination with pCBWN elicits a protective immune
response in mice and horses (Davis et al., 2001). Third, we
immunized mice with the DNA vaccine followed by
boosters with the formalin-inactivated vaccine. The neutral-
izing antibody response in the serum of mice immunized
with DNA was stronger after boosting with the formalin-
inactivated virus vaccine (data not shown); therefore, we
chose these animals for hybridoma production. Finally, we
produced a soluble WNV E protein for use as an
immunogen. Soluble proteins have been used to obtain the
crystal structures of Tick-borne encephalitis and Dengue E
proteins (Bressanelli et al., 2004; Modis et al., 2003, 2004;
Rey et al., 1995), which have revolutionized our under-
standing of the conformation and function of these proteins.
Soluble E proteins may present epitopes that are masked
when using antigens in particulate form (i.e., virus and
subviral particles) (Heinz et al., 1991, 1995) but should
preserve the overall conformation of the protein. However,
none of the MAbs produced to the soluble E protein were
neutralizing. This could be due to structural differences
between soluble and virion associated E proteins, the
presence of immunodominant epitopes in the soluble protein
that are masked when the E protein is on the surface of a
particle, differences in hybridoma screening, or the limited
number of antibodies that we obtained. Interestingly, these 3
MAbs exhibited significant cross-reactivity with other
flaviviruses, whereas the MAbs elicited by other immuno-
gens reacted only with WNV.
While neutralizing epitopes have been described in all
three domains of the E protein for other flaviviruses (for
review, see Roehrig, 2003), the majority of neutralizing
antibodies bind to domain III. The four neutralizing MAbs
described here (8B10, 11C2, 10C5 and 17C8) mapped to a
region on the lateral surface of domain III which has been
previously described as an important neutralizing epitope
for WNV (Beasley and Barrett, 2002; Chambers et al.,
1998) (see Fig. 1A and Table 3). Despite this, they
neutralized virus infection with different potencies, with
their ability to block virus infection directly correlating with
their affinity to the E protein (Table 1). It will be interesting
to determine if very high affinity binding of MAbs to WNV
is due to bivalent binding, since the complex structure of theprotein shell covering the virus makes bivalent binding on
different E proteins feasible (Mukhopadhyay et al., 2003).
In addition, subtle differences in the amino acid residues
bound by each MAb could also impact neutralization. We
expect that additional mutations will further differentiate the
specific epitopes for these neutralizing MAbs.
Non-neutralizing MAbs mapped to domains I or III and
had a variable affinity for the E protein (see Table 1).
Several MAbs that bound to the E protein with high affinity
exhibited no neutralizing activity (4E1, 9E5, 17D7). It is
possible that high affinity MAbs which do not neutralize
WNV in vitro may be protective in vivo by mechanisms
other than blocking interaction of the virus with the cell,
including complement or Fc-dependent mechanisms. There-
fore, for WNV, binding to the E protein with high affinity is
not sufficient for neutralization suggesting that both affinity
and the specific nature of the epitope are key components
for effective neutralization of WNV.
High occupancy theories of antibody neutralization
predict that complete coating of the virus by antibodies is
sufficient to neutralize virus, by blocking interactions with
the cell (Klasse and Sattentau, 2002). Our neutralization and
affinity data suggest that coating of West Nile virions with
high affinity antibodies is not the only determinant of
neutralization. It is not clear if non-neutralizing, high
affinity antibodies against flaviviruses allow functional
epitopes on the E protein to be exposed even when the
particle is covered with antibodies, thereby allowing virus
entry. It is also possible that steric hindrance prevents
complete coverage of the virus particle by these MAbs,
allowing some E proteins to interact with the cell and
mediate entry (Klasse and Sattentau, 2002).
Passive immunization with antibodies against WNV can
confer protection in animal models (Ben-Nathan et al.,
2003; Camenga et al., 1974; Diamond et al., 2003; Engle
and Diamond, 2003; Tesh et al., 2002; Wang et al., 2001).
Passive immunization with pooled human plasma prepara-
tions (intravenous immunoglobulin, IVIG) containing
neutralizing antibodies against WNV (Omr-IgG-am, Omrix
Pharmaceuticals) is currently undergoing clinical trials in
the United States (http://www2.niaid.nih.gov/newsroom/
releases/wnv_trials.htm) reflecting the success of this
approach in a limited number of clinical case reports
(Agrawal and Petersen, 2003; Haley et al., 2003; Hamdan
et al., 2002; Shimoni et al., 2001). Treatment with
humanized MAbs is a viable, more specific alternative
treatment for WNV infection than treatment with IVIG.
Treatment with humanized MAbs can eliminate the risk of
accidental transmission of infectious diseases which may
be present in the IVIG preparations. Potentially, humanized
MAbs may be used as an adjunct therapy to IVIG in order
to increase the titer of neutralizing and protective anti-
bodies in the preparations used for treatment. Safety and
effectiveness of humanized, neutralizing, high affinity
MAbs should therefore be investigated as a therapy for
WNV.
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WNV immunogens
Mice were immunized with three different forms of the
WNV E protein: a DNA plasmid encoding the prM and E
genes of Lineage I WNV strain NY99-6480 (pCBWN)
(Davis et al., 2001), a formalin-inactivated virus vaccine
licensed for use in horses (West Nile Innovator-Fort Dodge
Animal Health) (Ng et al., 2003), and purified soluble WNV
E protein. For the WNV soluble E protein, a PCR product
encoding the prM gene and a truncated E gene (truncated at
amino acid 440 of the NY99-6480 strain) with a 6X-
Histidine tag at the 3V end, was cloned into pSC65 using the
restriction enzymes SalI and BglII. A recombinant vaccinia
virus, vBAP29, was produced using this plasmid and the
Western Reserve vaccinia virus strain, using standard
techniques (Earl and Moss, 1993). To generate recombinant
protein, HEK 293T cells were infected with vBAP29 at a
multiplicity of infection of 5 for 1 h, then washed twice with
phosphate-buffered saline (PBS) and media replaced with
serum-free Dulbecco-modified Eagle medium (DMEM;
Gibco-BRL). Cell supernatants were harvested 48 h post-
infection, clarified by low-speed centrifugation, and filtered
through a 0.22-Am-pore size filter. Triton X-100 was added
to a final concentration of 0.1% to inactivate residual
vaccinia virus and sodium azide was added to 0.05% to
prevent microbial growth. Media were concentrated and
dialyzed against PBS with a Millipore tangential flow
filtration system and 30K Biomax Pellicon membrane.
Soluble E was purified from the diafiltrate on Talon resin
(Clontech) using a Biologic LP chromatography system
(BioRad). Resin was equilibrated with PBS, supernatant
applied, then washed with PBS, followed by a PBS 20 mM
imidazole wash, and protein eluted with 200 mM imidazole
in PBS. Eluate was concentrated and buffer exchanged with
PBS in a Centriplus 30 centrifugal concentrator (10 kDa
MW cutoff) and protein concentration determined by BCA
Protein Assay (Pierce) with a BSA standard curve. Purity of
the soluble E protein was assessed by silver stain analysis.
Monoclonal antibody production
Groups of 6- to 8-week-old BALB/c mice were divided
into three groups for immunization with one of three
different protocols. For immunization protocols using the
formalin-inactivated virus vaccine, mice were immunized
four times with 100 Al of the vaccine intramuscularly (IM)
at 3-week intervals, followed by two intraperitoneal (IP)
boosts with 100 Al of the vaccine at 3-week intervals, and a
final intravenous (IV) injection with 25 Al of the vaccine
4 days before hybridoma fusion protocols were performed.
Splenocytes from one mouse were harvested and fused with
SP2 myeloma cells as described previously (Yokoyama,
1994). Hybridomas were screened by enzyme-linked
immunosorbent assay (ELISA) for reactivity against WNVsubviral particles (SVP). Positive hybridoma cells were
cloned by limiting dilution to obtain antibodies derived from
a single cell.
For immunization protocols using the DNA plasmid
(pCBWN) and the formalin-inactivated virus vaccine,
100 Ag of DNA (pCBWN) was injected IM for three doses
at 3-week intervals, with three IM boosts with 100 Al of the
formalin-inactivated virus vaccine, one IP boost with 100 Al
of the formalin-inactivated virus vaccine and a final IV boost
with 25 Al of the killed virus vaccine 4 days before the
fusions were performed as described above. These hybrid-
omas were also screened for reactivity against WNV SVPs
using an ELISA and cloned by limiting dilution.
For immunization protocols using the soluble E protein,
100 Ag of purified protein in Ribi Adjuvant System
(MPL + TDM Emulsion, Corixa Corporation) was injected
intradermally (ID) for five doses at 3-week intervals, with
a final IV boost with 100 Ag of purified protein without
adjuvant. Four days after the final immunization, fusions
were performed following the same protocols for the
previous two fusions. These hybridomas were screened for
reactivity against purified WNV soluble E protein using an
ELISA, and cloned by limiting dilution. A total of five
fusions were performed, out of which nine stable hybridoma
cell lines were isolated and further characterized. MAbs were
isotyped by using an ELISA-based isotyping kit (Clonotyp-
ing System-HRP, Southern Biotechnology Associates).
Production of wild-type and mutant subviral particles
SVPs were produced by lipid-mediated transfection of
HEK 293 T cells with a DNA plasmid encoding wild-type
Lin I or Lin II prM/E, or mutants of these proteins,
following manufacturer’s instructions (Lipofectamine
2000, Invitrogen). For Lineage I WNV, strain NY99-6480
(pCBWN) was used, while for Lineage II WNV, strain 956
D117 3B (Yamshchikov et al., 2001) was used. Five to 6 h
after transfection, the media were changed to low-glucose
formulation of DMEM supplemented with 1% Penicillin/
Streptomycin (no serum). Supernatants containing SVPs
were harvested 48 h after transfection, clarified by low-
speed centrifugation, filtered through a 0.45 Am-pore size
filter, and stored at 4 8C. For the lineage I vs. lineage II
ELISA described below, SVPs were produced in low-
glucose DMEM supplemented with FBS, and pelleted by
ultracentrifugation through a 20% sucrose cushion at 38,000
rpm for 2 h at 4 8C in a Beckman SW41Ti rotor. The SVP
pellet was resuspended overnight in 150 mM NaCl, 10 mM
HEPES, pH 8.0.
SVPs with mutations in Domain III of the lineage I WNV
E protein were produced in low-glucose serum-free DMEM
as described above by transient transfection of HEK 293T
cells with a plasmid encoding wild-type prM and a mutated
E protein. The following amino acid residues in Domain III
were mutated on the pCBWN plasmid using the Quik-
Change Site-Directed Mutagenesis kit (Stratagene): S306A,
M.D. Sa´nchez et al. / Virology 336 (2005) 70–8278K307R, F309A, K310A, L312A, H320A, Q328A, Y329A,
T330I, T332A, T366A, N368A, K370A, I384A, V385A,
V386A, G389A, Q391A. Sequence analysis of the entire
open-reading frame confirmed that the only mutations
present were those listed above. Mutations of specific
amino acid residues were made based on analysis of the
structure of a homology model of the WNV E protein based
on the crystal structure of the Dengue E protein (PDB code,
1OAN) (Modis et al., 2003) obtained with the program 3D-
Jigsaw (http://www.bmm.icnet.uk/servers/3djigsaw/) and
visualized with Rasmol 2.6 (Sayle and Milner-White,
1995), the NMR structure of WNV Domain III (PDB code,
1S6N) (Volk et al., 2004), and MAb mapping results with
neutralization escape mutants from other flaviviruses and
WNV (Beasley and Barrett, 2002; Roehrig, 2003). Dilution
experiments of mutant SVPs suggested that similar levels of
protein were produced by all the mutant envelope proteins
(data not shown).
ELISAs
All ELISAs were performed in 96-well plates (Immulon
2 HB, Thermo Labsystems). SVP refers to those produced
by transfection with pCBWN unless otherwise noted. For
hybridoma screening, a 32-fold dilution of serum-free
supernatant containing SVPs was added to each well in
PBS pH 8.6 and allowed to bind overnight at 4 8C. We
found that this dilution of the SVP preparations in serum-
free supernatant consistently saturated binding of SVPs to
the wells of the ELISA plate (data not shown). After
overnight binding of SVPs, the plates were washed six times
using an automatic plate washer (Ultrawash PLUS Micro-
plate Washer, Dynex Technologies) with PBS/0.05% Tween
20, and blocked with BLOTTO (PBS with 5% nonfat dry
milk and 0.1% Tween 20) for 1 h at room temperature (RT).
Hybridoma supernatants (100 Al) were added after the
blocking step and allowed to bind for 2 h at RT. Plates were
washed six times, and ECL anti-mouse IgG from sheep
conjugated to horseradish peroxidase (HRP) (Amersham
Biosciences) was added at a dilution of 1:10,000 and
incubated for 1 h at RT. Following a final wash, TMB
Peroxidase Substrate and Peroxidase Substrate solution B
(KPL) were mixed at 1:1 dilution, 100 Al added to each
well, the reaction stopped with 50 Al 2MH2SO4 per well,
and optical density at 450 nm (OD450) measured. ELISAs to
screen for positive hybridomas using soluble E-His protein
were performed similarly to the SVP ELISAs, using instead
100 ng of purified soluble E protein per well as the antigen.
ELISAs to test binding of MAbs to SVPs with mutations
in Domain III were performed as described above for the
SVP ELISAs for hybridoma screening with the following
adjustments: a 4-fold dilution of the specific mutant SVPs
was added as the antigen in the ELISA plates, and incubated
with 30 Ag/ml of each MAb as the primary antibody. A 4-
fold dilution of mutant SVPs consistently saturated binding
to the wells of the ELISA plate. Some of the mutatedconstructs did not express enough protein and therefore
were excluded from this assay. The binding of each MAb to
the mutant SVPs was normalized to the reactivity of each
MAb with wild-type SVPs, with binding to wild-type SVPs
set to 100%.
ELISAs to test lineage I versus lineage II SVPs were
performed as described for the SVP ELISA for hybridoma
screening with the following adjustments: SVPs used were
made in the presence of FBS and pelleted through a 20%
sucrose cushion as described above, a 10-fold dilution of
lineage I and lineage II SVPs was coated on the wells, and
0.1 mg/ml of each MAb was used as the primary antibody.
Dilution experiments with both SVPs suggested they were
produced at similar levels (data not shown).
Competition binding ELISAs were performed in 96-well
plates to which SVPs in serum-free media had been
adsorbed in ELISA coating buffer (0.15 M sodium carbo-
nate, 0.35 M sodium bicarbonate in PBS pH 9.6) over-
night at 4 8C. Plates were washed with PBS/0.05%Tween
20 and blocked with PBS/0.05% Tween/1% BSA for 1 h at
RT. Unlabeled MAbs were diluted at 200 Ag/ml in PBS/
0.05% Tween/1% BSA and incubated at RT for 1 h. After
incubation with the unlabeled MAb, the indicated biotiny-
lated bcompetitorQ MAb was added at 2 Ag/ml without
washing and the plate was incubated for 30 min at RT.
Plates were then washed and a 1:2500 dilution of neutra-
vidin conjugated to HRP (Molecular Probes) was added and
incubated for 1 h at RT. Following a final wash, substrate
and stopping solution were added as described above,
and OD450 determined. MAbs were biotinylated using EZ-
Link Sulfo-NHS-LC-Biotin (Pierce) per manufacturer’s
instructions.
ELISAs to determine reactivity of MAbs with low pH
treated virus were done in BSL-3 facilities with low passage
lineage I WNV strain 3000.0259 NY 2000 (NY2000) (Ebel
et al., 2001). 360 ng/ml of NY2000 virus was added to each
well of a 96-well plate and treated at pH 4 or pH 8 for 1 h at
37 8C by the addition of pH4 or pH 8 buffers. pH buffers
consisted of DMEM no bicarbonate supplemented with
15 mM HEPES, 15 mM MES adjusted to either pH 4 or
pH 8. After 1 h, the virus was back-neutralized to pH8, and
ELISA coating buffer added. Virus was allowed to bind to
the wells of the ELISA plate O/N at 4 8C. The plate was
washed manually with PBS/0.05% Tween and blocked with
BLOTTO for 1 h at 37 8C. MAbs were added at 0.1 mg/ml
in BLOTTO, with the exception of 9E5 and 3F7 which were
added at 0.2 mg/ml to increase the signal obtained from
these MAbs, and incubated overnight at 4 8C. After washing,
ECL anti-mouse IgG from sheep conjugated to HRP was
added at a dilution of 1:10,000 and incubated for 1 h at RT.
After a final wash, substrate and stopping solutions were
added as described above and the OD450 determined.
Affinity ELISAs to calculate the steady-state equilibrium
constant value, Kd, of each MAb were performed by
binding a 32-fold dilution of SVPs made in serum-free
media to the wells of a 96-well plate. Plates were blocked
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screening described above. Dilutions of purified MAbs
(from 88.7 nM to 0.005 nM) were incubated for 1 h at RT as
the primary antibody. Secondary antibody and subsequent
developing of the ELISA were done as for the ELISA used
for hybridoma screening. The Kd was determined from the
concentration of MAb corresponding to 50% maximal
binding using GraphPad Prism 4.0 (GraphPad Software,
Inc). Repeats of the ELISAwith larger dilutions of SVPs did
not affect the Kd values obtained (data not shown).
Immunoblotting and immunoprecipitation
Immunoblotting was performed using lysates of HEK
293T cells transfected with pCBWN or mock transfected,
following the same transfection protocol used for production
of SVPs. Cells were collected 48 h after transfection and
lysed in 50 mM Tris pH7.5, 150 mM NaCl, 2 mM EDTA,
1% Triton in PBS. SDS-PAGE was performed under
completely denaturing (reducing agent added (DTT) and
heat treatment at 55 8C for 10 min) or partially denaturing
(non-reducing and kept at room temperature) conditions.
Blots were blocked in BLOTTO, cut into strips and
incubated with a 1:100 dilution of hybridoma supernatant
(6G10), 1:500 dilution of ascites (10C5, 17D7, 11C2, 17C8,
8B10) or 1:500 dilution of WNV-specific hyperimmune
ascitic fluid (W HIAF) (ATCC) in BLOTTO. Bound
antibody was detected with ECL anti-mouse IgG from
sheep conjugated to HRP (Amersham Biosciences) and
enhanced chemiluminescence (SuperSignal West Femto
Maximum Sensitivity Substrate, Pierce).
Immunoprecipitations were performed using lysates of
HEK 293T cells transfected with pCBWN or mock trans-
fected in a 6-well plate. Cells were metabolically labeled 24
h after transfection with 0.2 mCi per well of S35 methionine-
cysteine overnight, and harvested 48 h after transfection
(after overnight radiolabeling). Cell lysates were pre-cleared
by incubation with 50 Al of Protein A/G beads (Protein A/G
Plus-agarose, Santa Cruz Biotechnology) bound to 5 Ag of
mouse IgG (Sigma) for 30 min at 4 8C with rotation. Lysates
were subsequently incubated with 50 Al of Protein A/G
beads bound to 5 Ag of each MAb for 2 h at 4 8C with
rotation. Beads were then washed 4 times with PBS,
pelleted and 30 Al of sample buffer with DTT added. After
boiling, samples were analyzed by SDS-PAGE and radio-
activity detected with a PhosphoImager.
Immunofluorescence
For immunofluorescence experiments to determine reac-
tivity of MAbs, HeLa cells on coverslips were transfected
with pCBWN following the protocol used for production of
SVPs. Twenty-four hours after transfection, cells were fixed
in 2% paraformaldehyde for 20 min at RT, washed with PBS
and quenched with 50 mM ammonium chloride for 10 min.
Cells were subsequently washed and permeabilized with0.1% Triton for 5 min, washed with PBS and blocked with
5% FBS for 30 min. Cells were incubated with a 1:250
dilution of hybridoma supernatant from each MAb diluted
in 5% FBS for 30 min. Cells were washed with PBS before
a 30-min incubation with goat anti-mouse conjugated with
AlexaFluor 594 (Molecular Probes) at 1:500 dilution in 5%
FBS and a 1:500 dilution of DAPI (4V-6-Diamidino-2-
phenylindole). Cells were washed, mounted with ProLong
Antifade Kit (Molecular Probes) and examined on a Nikon
E600 epifluorescence microscope.
For immunofluorescence experiments to determine cross-
reactivity of MAbs with other flaviviruses, Vero cells were
infected with the specified virus and cells acetone fixed. All
purified MAbs (3F7, 4E1, 9E5) were diluted to 10 Ag/ml in
PBS. Ascites fluids (10C5, 11C2, 8B10, 6G10, 17D7,
17C8) were diluted 1:100 in PBS. Primary MAbs were
incubated for 30 min at RT, washed with PBS then
incubated with a second antibody-FITC conjugate consist-
ing of affinity purified goat antibody to mouse IgG + IgM
(Jackson ImmunoResearch) at 30 Ag/ml in counterstain
blocking diluent (ViroStat) for 30 min at RT and rinsed with
PBS. Mounting medium (ViroStat) was applied and slides
coverslipped and examined under an Olympus BX40
Fluorescence Microscope at 400. Positive control MAbs
included: Pan-Flavivirus (ViroStat), Pan-Alphavirus (Viro-
Stat), Pan-Bunyavirus (ViroStat), Pan-Dengue (ViroStat),
Yellow Fever Virus (ViroStat).
Protein production and purification
Monoclonal antibodies were purified from hybridoma
supernatants using Protein A agarose (Invitrogen) with a
Biologic LP chromatography system (BioRad). Prior to
purification, Protein A MAPS II Binding Buffer (BioRad)
was added to the supernatants according to manufacturer’s
instructions. Supernatants were subsequently filtered
through a 0.22-Am-pore size filter. Protein A agarose
columns were equilibrated with binding buffer, after which
the hybridoma supernatant was applied. Columns were
subsequently washed with binding buffer, and the MAbs
eluted with elution buffer (Protein A MAPS II Elution
Buffer, BioRad) in 10 ml fractions into tubes containing 1 ml
of 1 M Tris pH 8.0 to back-neutralize the eluted MAb.
Fractions containing eluted MAbs were concentrated and
buffer exchanged with PBS using Apollo High Performance
centrifugal spin concentrators (70 kDa MW cutoff, Con-
tinental Lab Products). Purity of MAbs was assessed by
silver stain, and concentration measured by ELISA.
To measure IgG concentration by ELISA, plates were
coated with a 1:500 dilution of coating antibody (Goat anti-
mouse Ig (H + L)-Human adsorbed, Southern Biotechnolo-
gy Associates) in ELISA coating buffer overnight at 4 8C.
The plates were blocked in PBS/1%BSA/0.05% Tween 20,
and dilutions of purified MAbs added and incubated for 1 h
at RT. The same protocol for washing, secondary antibody
and developing was used as described above for the ELISAs
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standard antibodies (Mouse Standard Panel, Southern
Biotechnology Associates) were used to create a standard
curve to determine the concentration of antibody in the
purified batches of MAbs.
To express the small fragments of the E protein as
bacterial fusion proteins, we used the pBAD/TOPO Thio-
Fusion expression system (Invitrogen). Briefly, the frag-
ments were amplified by PCR spanning the following
residues of the E protein from WNV strain NY99-6480
(pCBWN): WE1 (AA 34–137), WE2 (AA146–249), WED3
(AA 296–415), WED3-1 (AA 296–338), WED3-2(AA
333–380), WED3-3 (AA 376–415), WE4 (AA130–193),
WE5 (AA 188–248), WE6 (AA 242–301), WE7 (AA 1–
52). The fragments were cloned into the pBAD/Thio TOPO
expression vector by TA cloning. Insert containing plasmids
were used to transform TOP10 Escherichia coli cells and
1-liter cultures grown and induced with arabinose, as
specified by the manufacturer. Bacterial cell lysates were
screened for protein expression by non-reducing SDS-
PAGE, followed by detection with an anti-Histidine anti-
body which would detect the 6X-His tag on the C-terminus
of each protein. Subsequently, binding of the MAbs to each
fragment was assessed by SDS-PAGE under non-reducing
conditions. A 1:500 dilution of ascites was used for MAbs
17D7, 17C8, 8B10, 6G10, 10C5 and 11C2, while a 1:100
dilution of hybridoma supernatant was used for MAbs 4E1,
3F7 and 9E5. For protein purification of fragments WE1,
WE2 and WED3 for use in ELISA assays, 5-liter bacterial
cultures were grown, induced with arabinose, and the
proteins purified under denaturing conditions as specified
by the manufacturer. Briefly, the bacterial pellets were lysed
in denaturing lysis buffer (6 M guanidine hydrochloride,
100 mM NaH2PO4, 10 mM Tris–HCl), and the proteins
purified by applying cleared lysates to nickel-NTA beads
(Ni-NTA agarose, Qiagen) for 2 h with rotation. Beads
were subsequently washed with 8 M urea, 100 mM
NaH2PO4, 10 mM Tris–Cl, pH 8, and proteins eluted from
beads with 8 M urea, 100 mM NaH2PO4, 10 mM Tris–Cl,
pH 4.5. Purified proteins were dialyzed against PBS,
quantified and purity assessed by silver stain. Purified
fragments were used as antigen in ELISAs to detect binding
of MAbs following a protocol as described above for the
SVP ELISAs for hybridoma screening, except 500 ng of the
purified fragment was used as the antigen and plated in each
well instead of SVPs.
Plaque reduction neutralization assays
Plaque reduction neutralization assays were performed
using WNV NY2000. BHK-21 Clone 15 cells were plated
in a 12-well plate at 4  105 cells/well, and allowed to
attach for 3 h before infection. MAbs were diluted 4-fold
(with concentrations starting at 250 Ag/ml) in 0.5 ml of
DMEM with 10%FBS. 50–100 pfu of WNV was added to
the dilutions of MAbs, and incubated for 1 h at 37 8C.Media were then aspirated from the cells, and the virus/
MAb mixture added to the cells and allowed to infect for 1 h
at 37 8C. After 1 h infection, the media were aspirated, and
1.5 ml of a 1:1 mixture of 2% SeaPlaque Low Melting
Temperature agarose (Cambrex Bio Science Rockland, Inc)
and 2 Minimal Essential Medium (Gibco-BRL) with 8%
FBS was added slowly to each well. Plates were incubated
for 3 days at 37 8C in a CO2 incubator. Cells were then fixed
for 2–24 h with 10% formaldehyde, and after removal of
agarose plugs, stained with 1% crystal violet in 20%
ethanol. PRNT50 values were obtained by averaging values
from non-linear regression analysis of at least 4 replicates of
the assay for each MAb, with R2 values N 0.8 using
GraphPad Prism 4.0 (GraphPad Software, Inc).Acknowledgments
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